Literature DB >> 7621513

Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.

W Brysch1, K H Schlingensiepen.   

Abstract

1. Synthetic oligonucleotides can inhibit the expression of a gene in a sequence specific manner on the transcriptional and translational level. These molecules are usually referred to as antisense oligonucleotides. 2. Antisense mediated inhibition of gene expression is a valuable tool to analyze the function of a gene in vivo and can also be used for therapeutic gene suppression. 3. A number of factors such as the mode of action, specificity, chemistry, and pharmacology must be carefully considered for the design and successful application of antisense oligonucleotides. 4. Assay systems and controls must be chosen as to assure that the observed biological effects of antisense oligonucleotides do in fact reflect the result of a specific gene inhibition. 5. This article critically discusses these factors in view of the literature and our own experience with a wide range of cell types and animal models, targeting different genes. The emphasis is on the use of phosphorothioate oligodeoxynucleotides in cell cultures, in vivo, and as potential drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7621513     DOI: 10.1007/bf02088837

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  45 in total

Review 1.  In vitro and in vivo pharmacologic activities of antisense oligonucleotides.

Authors:  C K Mirabelli; C F Bennett; K Anderson; S T Crooke
Journal:  Anticancer Drug Des       Date:  1991-12

2.  Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B.

Authors:  I Kitajima; T Shinohara; J Bilakovics; D A Brown; X Xu; M Nerenberg
Journal:  Science       Date:  1993-03-12       Impact factor: 47.728

Review 3.  Cell membranes as barriers for antisense constructions.

Authors:  V G Budker; D G Knorre; V V Vlassov
Journal:  Antisense Res Dev       Date:  1992

Review 4.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

Authors:  C A Stein; Y C Cheng
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

5.  A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro.

Authors:  C W Helm; K Shrestha; S Thomas; H M Shingleton; D M Miller
Journal:  Gynecol Oncol       Date:  1993-06       Impact factor: 5.482

6.  Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.

Authors:  C Wahlestedt; E M Pich; G F Koob; F Yee; M Heilig
Journal:  Science       Date:  1993-01-22       Impact factor: 47.728

7.  Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels.

Authors:  E H Postel; S J Flint; D J Kessler; M E Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

8.  Comparative evaluation of seven oligonucleotide analogues as potential antisense agents.

Authors:  F Morvan; H Porumb; G Degols; I Lefebvre; A Pompon; B S Sproat; B Rayner; C Malvy; B Lebleu; J L Imbach
Journal:  J Med Chem       Date:  1993-01-22       Impact factor: 7.446

9.  Block of c-Fos and JunB expression by antisense oligonucleotides inhibits light-induced phase shifts of the mammalian circadian clock.

Authors:  F Wollnik; W Brysch; E Uhlmann; F Gillardon; R Bravo; M Zimmermann; K H Schlingensiepen; T Herdegen
Journal:  Eur J Neurosci       Date:  1995-03-01       Impact factor: 3.386

10.  Improved free-energy parameters for predictions of RNA duplex stability.

Authors:  S M Freier; R Kierzek; J A Jaeger; N Sugimoto; M H Caruthers; T Neilson; D H Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more
  6 in total

1.  Gene interference using antisense oligodeoxynucleotides on whole chick embryos. Optimal ring and roller-bottle culture technique.

Authors:  J Cooke; A Isaac
Journal:  Mol Biotechnol       Date:  2000-07       Impact factor: 2.695

Review 2.  Strategy for designing specific antisense oligonucleotide sequences.

Authors:  M Mitsuhashi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

3.  Investigating the mechanisms of retinal degenerations with antisense oligonucleotides.

Authors:  M M Jablonski
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

4.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 5.  The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.

Authors:  Traian V Chirila; Piroska E Rakoczy; Kerryn L Garrett; Xia Lou; Ian J Constable
Journal:  Biomaterials       Date:  2002-01       Impact factor: 12.479

6.  Computational genes: a tool for molecular diagnosis and therapy of aberrant mutational phenotype.

Authors:  Israel M Martínez-Pérez; Gong Zhang; Zoya Ignatova; Karl-Heinz Zimmermann
Journal:  BMC Bioinformatics       Date:  2007-09-28       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.